IP Library › Granted Patent US 11,826,436
Granted Patent B2
US 11,826,436 · App. 17/857,990 · Granted Nov 28, 2023

Methods and kits for preparing radionuclide complexes

Inventors: Philip Blower (London, GB); Gregory Mullen (Reading, GB)
A61K51/0478A61B5/0035A61K51/082A61K51/088A61P35/00C01G15/00C07B59/00C07C251/24C07F5/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,826,436
App. No.
17/857,990
Granted
Nov 28, 2023
Kind
B2
Abstract

A method for preparing a complex comprising a radioisotope of gallium for use in radiotherapy or in a medical imaging procedure, said method comprising adding a gallium radioisotope solution obtained directly from a gallium radionuclide generator to a composition comprising a pharmaceutically acceptable buffer and optionally also a pharmaceutically acceptable basic reagent, in amounts sufficient to increase the pH to a level in the range of 3 to 8, wherein the composition further comprises a chelator that is able to chelate radioactive gallium within said pH range and at moderate temperature, said chelator being optionally linked to a biological targeting agent. Kits and compositions for use in the method are also described and claimed.

Claims (9)

1. A method for preparing a complex comprising a radioisotope of gallium for use in a medical imaging procedure, said method comprising: adding a 0.1M HCl gallium radioisotope eluate obtained directly from a gallium-68 radionuclide generator, without additional preparation, purification or concentration steps, to a chelator composition, thereby forming the complex, wherein the chelator composition comprises:

a. a pharmaceutically acceptable buffer selected from a phosphate and an acetate buffer in an amount sufficient to increase the pH to a level in the range of 3 to 8;

b. DKFZ-PSMA-11 being a “chelator linked to a biological targeting agent” that is able to chelate radioactive gallium within said pH range and at a temperature of 10 to 30° C., and

c. ascorbic acid or gentisic acid;

wherein the chelator composition is in lyophilized or freeze-dried form, the gallium radioisotope solution is added directly to the lyophilized or freeze-dried chelator composition; and wherein the chelator composition does not include agents inhibiting metals other than gallium.

2. A method according to claim 1 , wherein the buffer is in an amount to give 0.1 to 0.5M buffer solution.

3. A method according to claim 1 , wherein the ascorbic acid or gentisic acid is present in the lyophilized or freeze-dried composition at a weight of from 1-4% w/w.

4. A method according to claim 1 , wherein the ascorbic acid or gentisic acid is present at a weight of from 1-2 mg.

5. A method according to claim 1 , wherein the chelator composition does not include an additional basic reagent.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2024
From: KING'S COLLEGE LONDON
To: THERAGNOSTICS LIMITED
Reel/Frame 068431/0616 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2023
From: MULLEN, GREGORY
To: THERAGNOSTICS LIMITED
Reel/Frame 062281/0569 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2023
From: BLOWER, PHILIP
To: KING'S COLLEGE LONDON
Reel/Frame 062281/0597 →
Priority Claims (1)
GB 1504064 · Mar 10, 2015 · national
Continuity (3)
Continuation 17154926 · Jan 21, 2021
Continuation 15554573
Related Publication 20220339304A1 · Oct 27, 2022
Cited By (1)
US 12,642,876